Keytruda

Earnings season has always been a market-moving catalyst for stocks. Depending on the numbers and their quality, stocks could swing wildly in either direction and create volatility — not a palatable proposition for traders. The risk is always there. However, one can trade the volatility by...

This week, the FDA granted approval for Merck & Co., Inc. (NYSE: MRK)’s Keyruda for chemotherapy combination treatment of frontline lung cancer. While the approval was far from a surprise, it may be enough to move the needle for both Merck and rival Bristol-Myers Squibb Co (NYSE: BMY)....

Merck & Co., Inc. (NYSE: MRK) traders that haven't already done so should mark May 10 on their calendars. The company announced in early January the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab)....

Merck & Co., Inc. (NYSE: MRK)'s KEYTRUDA is a therapy used to combat a form of skin cancer called melanoma. It can also be used to treat a kind of lung cancer called non-small cell lung cancer. The U.S. Food and Drug Administration announced on Nov. 28, 2016, it has granted a Priority Review...

Analyzing the monthly immuno-oncology sales data, Leerink said Merck & Co., Inc. (NYSE: MRK)'s Keytruda is picking up speed, but Bristol-Myers Squibb Co (NYSE: BMY)'s Opdivo is flattish. Immuno-Oncology Market On Strong Wicket Analyst Richard Goss noted that Symphony Health sales showed...

Lung and bronchus cancer is the leading cause of cancer deaths in the United States, according to the National Cancer Institute. Lung cancer is of two types, namely non-small cell lung cancer, or NSCLC and small cell lung cancer, or SCLC, with the former more prevalent than the latter. Estimates by...

After the close on Wednesday, Merck & Co., Inc. (NYSE: MRK) announced that the FDA had accepted its filing for Keytruda based on the KEYNOTE 021G data presented by the company at ESMO comparing the drug candidate plus chemo to chemo alone in 1L lung cancer. Piper Jaffray’s Richard J....

Merck & Co., Inc. (NYSE: MRK) unexpectedly announced a priority review for Keytruda plus chemo in first-line lung cancer. This, along with the previous announcements related to Keytruda, extends the company’s leadership position in immuno-oncology, Morgan Stanley’s David Risinger...

Shares of Merck & Co., Inc. (NYSE: MRK) are rallying strongly, while Bristol-Myers Squibb Co (NYSE: BMY) is being punished on Wednesday. News Behind The Move The contrasting moves come after Merck announced late Tuesday that the FDA has accepted to review the sBLA for KEYTRUDA, plus...

There are two big news from the staple of Merck & Co., Inc. (NYSE: MRK) during the weekend. While the first related to KEYNOTE-045 meeting primary endpoint, the second is in respect of FDA approval for ZINPLAVA to reduce recurrence of clostridium difficile (C. Diff.) infection in adults....

The ESMO 2016 Oncology Conference took place over the weekend in Copenhagen, Denmark. News out of the conference is making a big splash in the market on Monday. Here’s a look at what you may have missed. Bristol-Myers Squibb Co (NYSE: BMY) shares are down 10.17 percent after the company...

BMO Capital’s M. Ian Somaiya expects higher probability of success for Incyte Corporation (NASDAQ: INCY)'s epacadostat+Keytruda trials in melanoma, given the PFS strength in the updated Phase I data presented at the meeting of the European Society for Medical Oncology. Somaiya maintains an...

Merck & Co., Inc. (NYSE: MRK) shares are pushing higher by 1.9 percent on Monday following the company’s encouraging new data on Keytruda. On Sunday, Merck reported that Keytruda reduced patient deaths by 40 percent compared to chemotherapy alone and cut disease progression in half....

After Bristol-Myers Squibb Co (NYSE: BMY) disclosed disappointing study results of its Opdivo, SunTrust has reduced the price target on the company's shares from $68 to $62 on lower EPS estimates for the year 2017 and 2018. However, the firm maintains its Hold rating on the stock. Analyst John...

Seattle Genetics, Inc. (NASDAQ: SGEN) received a ratings bump from Goldman Sachs to Neutral from Sell after the brokerage revised its Adcetris U.S. sales estimates in 1L Hodgkin's lymphoma (HL) "to reflect greater market penetration per physician diligence." "We model 40 percent penetration (vs. 19...